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A series of 136 nervous system tumours were studied to determine the methylation status of the CpG island contained within the
promoter region of the RB1 gene, as well as mutation analysis of the essential promoter region and exons 20–24 (and surrounding
intronic regions) coding for the protein-binding pocket domain. Methylation of the RB1 CpG island was detected in 26 samples
corresponding to nine glioblastomas, three anaplastic astrocytomas, one mixed oligo-astrocytoma, one ependymoma, two
medulloblastomas, two primary central nervous system lymphomas, two neurofibrosarcomas, and six brain metastasis from solid
tumours. No inactivating mutations were found within the RB1 promoter region, whereas one glioblastoma and one
oligodendroglioma displayed similar sequence variations consisting of 12 and 8 base pair deletions at intron 21. These results
suggest that RB1 CpG island hypermethylation is a common epigenetic event that is associated with the development of malignant
nervous system tumours.
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The retinoblastoma susceptibility gene (RB1) is located on the long
arm of chromosome 13 (at 13q14) and represents the classical
example of a tumour suppressor gene. It spreads over 200kb and
encodes a nucleoprotein (pRB) that plays a key role in the cell
cycle regulation complexes that govern the G1–S transition of
cells, thus allowing mitosis and cell division. In late G1, pRB is
phosphorylated by the cyclin D1/cyclin-dependent kinase 4/6
complex, producing the release of nuclear proteins and transcrip-
tion factors (E2F family); this results in the progression of the cell
cycle into the S phase. On the other hand, the hypophosphorylated
form of pRB induces a G1 cell cycle arrest (Friend et al, 1986; Lee
et al, 1987; Buchkovich et al, 1989). The activity of the cyclin D1/
cyclin-dependent kinases complex is controlled by inhibiting
proteins such as p16 (CDKN2A), and the loss of p16 or RB1
function would result in a deregulated cell proliferation (Medema
et al, 1995).
Loss of RB1 function has been described in a variety of tumour
types, and significant association has been observed between loss
of heterozygosity (LOH) of RB1 intragenic markers and the
absence of pRB expression. LOH at the RB1 locus has been found
in 25–45% of glioblastomas and in about 25% of anaplastic
astrocytomas (AA), as well as in bladder carcinomas, and
malignant neuroendocrine lung carcinomas (Ishikawa et al, 1991;
Hogg et al, 1993; Xu et al, 1993; Gouyer et al, 1994; Henson et al,
1994; Ichimura et al, 1996). Sequencing analysis of all 27 exons of
the RB1 gene in those neoplasms with LOH at the RB1 locus
showed a low rate (5–12%) of inactivating mutations, suggesting
the location of another tumour suppressor gene at 13q14 or the
existence of another RB1 silencing mechanism, such as promoter
hypermethylation (Ishikawa et al, 1991; Ichimura et al, 1996;
Tsuzuki et al, 1996; Ueki et al, 1996). The loss of pRB expression
may also be the result of mutation or microdeletion of the RB1
promoter region, as described in hereditary retinoblastoma and
prostate cancer (Bookstein et al, 1990a; Sakai et al, 1991).
Alternatively, these molecular alterations have also been described
involving the RB1 protein-binding pocket domain, producing
structurally and functionally altered pRB proteins (Yandell et al,
1989; Hensel et al, 1990; Mori et al, 1990). Loss of pRB expression
with no association to LOH of the RB1 intragenic markers has been
described in breast carcinomas, prostate cancer, and pituitary
adenomas, reinforcing the existence of alternative RB1 gene-
inactivating mechanisms (Borg et al, 1992; Cooney et al, 1996;
Simpson et al, 1999).
Methylation of gene regulatory elements is an epigenetic change
representing an alternative to genetic alteration for gene inactiva-
tion. Methylation of CpG islands located within a promoter
element is generally associated with delayed replication and
inhibition of transcription initiation (Baylin et al, 1998; Delgado
et al, 1998; Jones and Laird, 1999). The RB1 gene could be
inactivated by a combination of genetic and epigenetic alterations
of two alleles; in fact, the RB1 gene harbours a CpG island that
encompasses the essential promoter region, which is unmethylated
during development (Jones, 1996). Experimental data show that in Received 21 May 2002; accepted 5 November 2002
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yvitro methylation of the RB1 promoter region reduces pRB
expression (Ohtani-Fujita et al, 1993) and unilateral retinoblasto-
ma frequently shows loss of pRB expression associated with
aberrant methylation of CpG island within the RB1 promoter
region (Stirzaker et al, 1997).
To determine the mechanisms participating in an inactivation of
the RB1 gene in malignant brain tumours, we investigated the
methylation status at the CpG island within the promoter region of
the RB1 gene. We also examined the essential promoter region and
the protein-binding pocket domain (exons 20–24 and surrounding
intronic sequences) for the presence of inactivating mutations.
MATERIALS AND METHODS
Tissue samples and DNA preparation
Fresh tumour tissues and blood samples were obtained from 136
patients with tumours of the nervous system, including: 42 (32
primary and 10 secondary) glioblastomas multiformes (GB), 21
WHO grade III AA, 22 WHO grade II oligodendrogliomas (O), 12
WHO grade III anaplastic oligodendrogliomas (AO), six WHO
grade II–III mixed oligo-astrocytomas (OA), four WHO grade II
ependymomas (E), three WHO grade III anaplastic ependymomas
(AE), 11 medulloblastomas (MD), three primary central nervous
system lymphomas (PCNSL), two neurofibrosarcomas (NFS), and
10 brain metastasis from solid tumours (MET). Tumours were
diagnosed according to the WHO guidelines (Kleihues et al, 1993),
and the tumour cell content was estimated by histologic
examination to be approximately 75–90%. DNA was prepared
from frozen tissues and blood samples using standard methods, as
described (Rey et al, 1992).
PCR/SSCP analysis and direct sequencing
The genomic DNA derived from tumour tissues and blood samples
was used as template for PCR-based amplifications of the essential
promoter region (encompassing nucleotides 300 to 174) and
the protein-binding pocket domain (exons 20–24 and surrounding
intronic sequences) of the RB1 gene. We used the primers and PCR
conditions as described by Simpson et al (2000) (purchased from
SIGMA ARK, St Louis, MO, USA). For SSCP analysis, the PCR
products were loaded onto 6–12% nondenaturing polyacrylamide
gels (with or without 10% glycerol), electrophoresed, and silver-
stained. Samples displaying an altered PCR-SSCP pattern were
reamplified by PCR with the same set of primers, and the PCR
products were sequenced using an ABI PRISM BigDye Terminator
Cycle Sequencing Ready Reaction Kit (Perkin-Elmer Applied
Biosystems, Foster city, CA, USA) on the Applied Biosystem
model 373A DNA sequencer. Each amplicon was sequenced
bidirectionally.
Bisulphite treatment of DNA and methylation-specific
(MSP) PCR
Bisulphite modification of genomic DNA was performed as
reported by Herman et al (1996). Briefly, 2mg of genomic DNA
was denatured with 2moll
1 NaOH (371C for 10min), followed by
incubation with 3moll
1 sodium bisulphite (pH 5.0) at 501C for
16h in the dark. After treatment, DNA was purified using the DNA
cleanup kit (Promega, Madison, WI, USA) as recommended by the
manufacturer, incubated with 3moll
1 NaOH (room temperature
for 5min), precipitated with 10moll
1 ammonium acetate and
100% ethanol, washed with 70% ethanol and resuspended in 20ml
distilled water. Primer sequences of RB1 for the methylated and
unmethylated reaction were as reported (Simpson et al, 2000). The
PCR amplification was carried out in a thermal cycler using
Amplitaq polymerase with denaturation at 951C for 5min, followed
by 35 cycles of 951C for 30s, 551C for 30s, and 721C for 30s. The
reaction was finished with a 7min extension at 721C. PCR products
were electrophoresed on 3% agarose gels and visualised with
ethidium bromide. To verify the identity of the PCR products, they
were purified and sequenced as above for mutation analysis. In
addition to tumours, two samples of non-neoplastic cerebral tissue
obtained by autopsy were studied. As positive/negative controls for
methylated alleles we used DNA (from lymphocytes of healthy
volunteers), treated/not treated with Sss1 methyltransferase
(New England Biolabs, Beverly, MA, USA) and then subjected to
bisulphite treatment.
RESULTS
RB1 sequence analysis
Promoter region. No case showed mobility shifts by PCR-SSCP
analysis of the RB1 promoter region and, thus no inactivating
mutations were found in any tumour examined.
Protein-binding pocket domain. Only two tumours presented
PCR-SSCP variations of the exons 20–24; they corresponded to
one GB and one O displaying similar alterations. A mobility shift
in the SSCP pattern of the PCR product for exon 22, which also
includes the surrounding sequence for intron 21, was observed in
both tumours (Figure 1). Sequence analysis demonstrated a
deletion involving 12bp (in GB) and 8bp (in O) at position 16
to 27, and 16 to 23 of intron 21 (IVS21-16–27del and IVS21-
16–23del), respectively.
RB1 promoter hypermethylation
RB1 promoter hypermethylation was detected in 26 of the 136
cases studied (19%). Among glial tumours, aberrant methylation
was evidenced in nine GB (five primary GB; four secondary GB),
three AA, one OA, and one E. The remaining 12 cases
corresponded to two MD, two PCNSL, two NFS, and six MET
(two malignant melanoma, three ovarian carcinomas, and one
breast carcinoma). Table 1 shows a summary of the main findings.
Methylated and unmethylated control DNAs displayed the
expected fragment size of 172bp, and sequencing of bisulphite-
modified DNA of the tumours and control (non-neoplastic brain)
PCR products demonstrated hypermethylation or normal se-
quences, respectively (Figure 2).
DISCUSSION
Abnormalities in expression of cell-cycle regulatory genes occur
commonly in human malignancies. In addition to the childhood
tumour retinoblastoma, RB1 inactivation has also been demon-
strated in a variety of tumours including sarcomas, lung, breast,
and bladder carcinomas, as well as malignant gliomas (Cance et al,
1990; Xu et al, 1991; Logothetis et al, 1992; Trudel et al, 1992;
Ichimura et al, 1996; Tsuzuki et al, 1996; Ueki et al, 1996). The
inactivation of both RB1 alleles in tumour cells was initially
detected in association with LOH at the RB1 locus on chromosome
13, and microdeletions or inactivating mutations in the retained
allele would be responsible for complete inactivation of the gene
(Ishikawa et al, 1991; Hogg et al, 1993; Xu et al, 1993; Gouyer et al,
1994; Henson et al, 1994; Ichimura et al, 1996). Loss of 13q arm has
been found in about 0–30% of solid tumours, including nervous
system neoplasms in which up to 45% of GB display loss at the RB1
locus (Ishikawa et al, 1991; Hogg et al, 1993; Xu et al, 1993; Gouyer
et al, 1994; Henson et al, 1994; Ichimura et al, 1996). We have
previously screened this series of tumours for allelic constitution at
chromosome 13 (Bello et al, 1994, and unpublished data) analysing
two polymorphic loci (D13S4 and D13S63) as well as the RB1 locus
with a cDNA probe used for densitometric analysis on TaqI/MspI
Southern blots. We detected 16% of samples characterised by 13q
losses, primarily involving GB (eight cases), AA (four samples), O
(one case), AO (two cases), E (one tumour), MD (one case), and
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yMET (five tumours). We did not detect any homozygous deletion
in our series.
Initial studies suggested that allelic losses of chromosome 13q
arm were accompanied by inactivating mutations in the gene
(Ishikawa et al, 1991; Hogg et al, 1993; Xu et al, 1993; Gouyer et al,
1994; Henson et al, 1994; Ichimura et al, 1996). Nonetheless, the
finding of tumours displaying LOH at the RB1 locus without any
abnormality in the remaining RB1 allele, but with the absence of
NT
TF
TR
NF
NR
RBI IVS21-16-27del
AA C G C T TT T TTTTTTTTTTTT TTTTT T AA AAA A C AG N
100 90 80 70
C GA AA AA A TAAAAAAAAAAAAN NN N N N AAAAA A AA CG G G NN TT GG G G C T
160 170 180 190 200
AAC GT TTN C T TTTTTTTTTTTTTTTTTTTT N ACC CCC GGG TT T NN AA AAA A
110 100 90 80 70
CC G TA A AA AA A A A A A A A A A A A A A A A A A A A A G G G G NNNTT GG G GTN
190 180 170 160
Figure 1 RB1 intron 21 mutation in one glioblastoma. A deletion of 12bp, at position –16 to –27 of intron 21, was identified by sequencing. To the left is
shown the SSCP analysis corresponding to the constitutional (N) and tumoural (T) DNAs (mobility shifts are indicated by arrows). Forward and reverse
sequences corresponding to the tumour and constitutional DNA show the nucleotide changes.
Table 1 Promoter hypermethylation of the RB1 gene in nervous system tumours
No. of cases with
Histology No. of cases
Promoter
hypermethylation LOH at 13q
a Hypermethylation+LOH 13q
Primary GBM 32 5 (15%) 5 (15%) 1
Secondary GBM 10 4 (40%) 3 (30%) 1
GBM total 42 9 (21%) 8 (19%) 2
AA 21 3 (14%) 4 (19%) 0
O 22 0 1 (5%) F
AO 12 0 2 (17%) F
OA 6 1 (16%) 0 F
E 4 1 (25%) 1 (25%) 0
AE 3 0 0 F
MD 11 2 (18%) 1 (9%) 0
PCNSL 3 2 (66%) 0 F
NFS 2 2 (100%) 0 F
MET 10 6 (60%) 5 (50%) 2
Total 136 26 (19%) 22 (16%) 4
GBM=glioblastoma; AA=WHO grade III anaplastic astrocytoma; O=WHO grade II oligodendroglioma; AO=WHO grade III anaplastic
oligodendroglioma; OA=WHO grade II–III mixed oligo-astrocytoma; E=WHO grade II ependymoma; AE=WHO grade III Anaplastic ependymoma;
MD=medulloblastoma; PCNLS=primary central nervous system lymphoma; NFS=Neurofibrosarcoma; MET=Brain metastasis from solid tumour.
aResults from Bello et al (1994) and unpublished data.
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ypRB expression (Borg et al, 1992; Cooney et al, 1996; Ueki et al,
1996; Burns et al, 1998; Simpson et al, 1999), supports the
existence of mutations in regions such as promoter or introns,
which are frequently not explored or escape SSCP studies.
Moreover, RB1 gene function loss has been found involving
mutations in both alleles with retention of heterozygosity at the
RB1 locus, as described in bladder carcinomas (Ishikawa et al,
1991). Mutations or microdeletions at exons 20–24 have primarily
been associated with an absence of pRB or reduced RB1 transcript
(Yandell et al, 1989; Hensel et al, 1990; Mori et al, 1990; Bookstein
et al, 1990b). We found no alterations at the essential promoter
region, and only two tumours (diagnosed as GB and O) displayed
sequence anomalies at the protein-binding pocket domain (exons
20–24) we screened by SSCP; both tumours retained two RB1
alleles. Henson et al (1994) studied all 27 exons and flanking
intronic regions of the RB1 in a series of 85 astrocytic tumours and
glioblastomas. Three of the four mutations they identified were
located in this region, involving exon 24 (two instances) and intron
24 (one case). Tsuzuki et al (1996) analysed 23 brain tumour
specimens with astrocytic differentiation. Sequence variations were
identified in three instances, one of them involving codon 754 in
exon 22: GTA-to-GGA transversion, resulting in a Val-to-Gly
substitution. Ichimura et al (1996) performed RB1 mutation
analysis of 195 astrocytic gliomas. In addition to three homo-
zygous deletions, RB1 gene mutations were detected in 12% of
samples; one of these was located at exons 20–24. This consisted of
a duplication–insertion of 24 bases in exon 21 that led to an in-
frame insertion of eight amino acids. All these reports thus show
little mutational involvement of the RB1 essential promoter region,
and a low frequency of alterations at the protein-binding domain
(exons 21–24) in astrocytic neoplasms.
The discrepancies observed among the rates of LOH at 13q (30%
of cases), RB1 inactivating mutations (5–12% of cases), homo-
zygous RB1 deletions (3% of tumours), and loss of RB1 expression
detected by immunohistochemical analysis (up to 27% of
samples), strongly suggest that other molecular mechanisms may
participate in the inactivation of this gene; moreover, loss of RB1
expression does not always correlate with LOH at the RB1 locus
(Henson et al, 1994; Ichimura et al, 1996; Nakamura et al, 1996;
Ueki et al, 1996; Burns et al, 1998).
Methylation of gene regulatory elements has been recognised as
an important mechanism participating in gene inactivation
(Esteller and Herman, 2002). Initial studies using methylation-
sensitive restriction enzyme digest techniques demonstrated that
methylation at the promoter region and exon 1 of RB1 gene is
associated with reduced levels of RB1 transcript (Greger et al,
1994). At present, hypermethylation is accepted as a mechanism
of RB1 gene inactivation and, in pituitary adenomas, loss of
pRB expression has been found to be associated with methyla-
tion of the CpG island within the RB1 promoter region together
with deletion within the protein-binding pocket domain (Simpson
et al, 2000).
Our study showed an overall RB1 gene methylation rate
incidence of 19%, with the highest frequency detected in the
MET group (60%). This finding would concur with the high grade
of malignancy characteristic of metastatic tumours. They would
accumulate several genetic alterations and probably epigenetic
changes involving inactivation of regulatory elements of key genes
participating in cell-cycle regulation and cell growth control (Seike
et al, 2000). A high methylation rate was also observed in NFS (two
cases of two analysed) and PCNSL (two cases of three studied).
Although the low number of samples available for analysis makes
it difficult to draw firm conclusions, the data suggest that
epigenetic inactivation of RB1 gene in parallel to methylation is
a frequent mechanism that contributes to tumour development or
progression in these neoplasms. With regard to malignant glial
tumours, we found significant RB1 methylation rates in the group
of GB (21% of samples). These figures are slightly lower than those
reported by Nakamura et al (2001), who identified promoter
hypermethylation in the RB1 gene in one-quarter (14 of 56 cases)
of the GB they studied. These authors also demonstrated that the
majority of GB with loss of RB1 expression had RB1 promoter
hypermethylation, whereas the majority of tumours with RB1
expression had normal RB1 gene status. We might thus consider
that most cases with hypermethylated RB1 promoter in our series
most probably would show loss of pRB expression, although we
had no possibility to perform pRB expression studies in our series
of tumours to demonstrate this. Our findings therefore support the
hypothesis that promoter hypermethylation is an epigenetic
mechanism frequently involved in the loss of RB1 function in
GB. In agreement with the data provided by Nakamura et al (2001),
we detected RB1 methylation more frequently in secondary than in
primary GB (40 vs 15% of cases, respectively). We found
hypermethylation in three of the 21 (14%) AA we studied, whereas
no case of the 10 AA tumours gave positive results in the series of
Nakamura et al (2001). One E and one OA in our series were also
characterised by RB1 promoter hypermethylation, whereas no O
nor AO displayed this alteration. No previous data are available on
RB1 methylation in E, and our findings in tumours with a major
oligodendroglial component contrast with those reported by Dong
et al (2001), who detected methylation in 34% (14 of 26) cases
studied. On the other hand, Watanabe et al (2001) identified this
anomaly in three of 48 tumours, suggesting that promoter
alteration of RB1 is rare in oligodendrogliomas, and demonstrated
that inactivation of the RB1-mediated G1-4S cell-cycle transition
pathway is more frequently caused by CDK4 amplification or
p16
INK4A/p15
INK4B inactivation.
Loss of RB1 expression is associated with a higher grade of
malignancy and appears to be a prognostic factor in several human
neoplasms (Cryns et al, 1994; Nakamura et al, 2001). If our finding
on RB1 methylation in three AA is confirmed in a larger series, it
may be representative of an AA subgroup with a more aggressive
biological behaviour.
A
B
172pb-
Normal
Control
Positive
Control P64 P62 P37 P32 P12
LU U U U U U UM M M M M M M
UR
MR
C CC AA C C C C C C C C C C TT N AA AAA A A A AA A AAAAAAA A
70
70 80 60 50
80 90 100
NC C C CG GNA AA AAAAAA TTT CC CC C C GG T GA AA AAA GC
Figure 2 (A) Methylation-specific PCR of CpG island of the RB1
promoter in glioblastomas (P12 and P32) and anaplastic astrocytoma (P37).
Cases P62 and P64 (glioblastomas) showed only unmethylated alleles.
Positive control for methylated DNA: normal DNA from lymphocytes
treated with SssI methyltransferase; normal control: DNA from a non-
neoplastic brain tissue. Negative control from untreated lymphocytes DNA
is not shown (L: molecular weight marker). (B) Sequence (reverse of the
coding strand) analysis of bisulphite-modified DNA from tumour P12 (MR)
and from non-neoplastic brain tissue (UR). Tumour DNA shows
methylated cytosines (G in the reverse sequencing marked by arrows) at
the represented CpG sites, whereas all CpG cytosines are unmethylated in
DNA from non-neoplastic brain tissue (A in the reverse sequencing
marked by arrowheads).
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